Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population‐based case–control study
Open Access
- 5 February 2015
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 137 (5) , 1187-1195
Abstract
Antiarrhythmic drug digoxin has been reported to have apoptosis-inducing and cytotoxic effects on prostate cancer cells. We evaluated the association between antiarrhythmic drug use and prostate cancer risk in a population-based case–control study. The study included all new prostate cancer cases diagnosed in Finland during 1995-2002 and matched controls (24,657 case–control pairs) obtained from the Finnish Cancer Registry and the Population Register Center, respectively. Information on antiarrhythmic drug purchases was obtained from national prescription database. Multivariable-adjusted conditional logistic regression model was used for data analysis. Compared to never-users of antiarrhythmic drugs, we found no significant association between digoxin use and prostate cancer risk overall [odds ratio (OR) 0.95, 95% confidence interval (CI): 0.89–1.01] or for advanced prostate cancer risk (OR: 0.90, 95% CI: 0.77–1.05). The result was similar also for other antiarrhythmic drugs, with the exception of sotalol, users of which had decreased risk of advanced prostate cancer (OR: 0.73, 95% CI: 0.56–0.96). Also the overall prostate cancer risk decreased by duration of sotalol use (p for trend 0.038). We show that digoxin or other common antiarrhythmic drugs generally do not associate with prostate cancer risk at population level during maximum follow-up of eight years. However, we cannot rule out longer term protective effects of digoxin. K+-channel blocker sotalol shows some promise as prostate cancer preventing agent. However, findings need to be confirmed in further studies.Keywords
Funding Information
- Maud Kuistila Memorial Fund (NA)
- The Finnish Cultural Foundation (NA)
- The Finnish Surgical Society (NA)
This publication has 17 references indexed in Scilit:
- A Novel Two-Stage, Transdisciplinary Study Identifies Digoxin as a Possible Drug for Prostate Cancer TreatmentCancer Discovery, 2011
- Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohortBreast Cancer Research and Treatment, 2011
- Cardiac Glycosides Decrease Prostate Specific Antigen Expression by Down-Regulation of Prostate Derived Ets FactorJournal of Urology, 2010
- Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entryOncogene, 2009
- Malignancy Grade–Dependent Expression of K+-Channel Subtypes in Human Prostate CancerJournal of Pharmacological Sciences, 2009
- Antidiabetic Medication and Prostate Cancer Risk: A Population-based Case-Control StudyAmerican Journal of Epidemiology, 2008
- Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control StudyCancer Epidemiology, Biomarkers & Prevention, 2007
- Prostate cancer risk among users of finasteride and alpha-blockers – A population based case–control studyEuropean Journal of Cancer, 2007
- Involvement of Cdk5/p25 in Digoxin-triggered Prostate Cancer Cell ApoptosisJournal of Biological Chemistry, 2004
- Data Quality and Quality Control of a Population-Based Cancer Registry: Experience in FinlandActa Oncologica, 1994